A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin.

Trial Profile

A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin.

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Peginterferon alfa; Ribavirin; Vitamin D analogues
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Sep 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01439776, ML25569).
    • 22 Sep 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 22 Sep 2011 Planned end date 1 Aug 2013 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top